Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNJ013
MIFTS: 66

Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Conjunctivitis

About this section

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis 12 73 29 54 3 44 15 62 17 70 32
Madras Eye 12

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Eye diseases Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:6195
ICD9CM 34 372.30
MeSH 44 D003231
NCIt 50 C34504
SNOMED-CT 67 193857008
UMLS 70 C0009763
Sources

Summaries for Conjunctivitis

About this section
PubMed Health : 62 About conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other. Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks. Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to giant papillary conjunctivitis and vernal conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pheniramine and Ferrous fumarate have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

CDC : 3 People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Wikipedia : 73 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Conjunctivitis

About this section

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 953)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 32.6 RNASE3 IL6 IL4 CXCL8 CCL11
2 vernal conjunctivitis 32.5 RNASE3 IL4 IGHE IFNG
3 bacterial conjunctivitis 32.5 TNF IL6 IL10 CXCL8
4 papillary conjunctivitis 32.4 IL6 IL4 CXCL8 CCL11
5 blepharitis 32.0 TNF IL4 CXCL8
6 pollen allergy 31.8 RNASE3 IL5 IL13 IGHE ICAM1
7 avian influenza 31.7 TNF IL6 CXCL8
8 muckle-wells syndrome 31.6 TNF NLRP3 NLRP12 CXCL8
9 kawasaki disease 31.6 TNF IL6 IL4 IL10
10 trichinosis 31.5 IL5 IL4 IL13 IL10 CCL11
11 measles 31.4 TNF TLR4 TLR3 IL6 IL2 IFNG
12 trachoma 31.4 TNF IL6 IL4 IL10
13 chronic conjunctivitis 31.3 TNF RNASE3 IL6 IL5 IL4 IL33
14 haemophilus influenzae 31.3 TNF CXCL8
15 periodic fever, familial, autosomal dominant 31.3 TNF TLR4 NLRP3 NLRP12 IL6 CXCL8
16 reactive arthritis 31.3 TNF TLR4 IL6 IL10 IFNG CXCL8
17 vernal keratoconjunctivitis 31.1 RNASE3 IL5 IL4 IL13 IGHE CCL11
18 allergic rhinitis 31.1 RNASE3 IL5 IL4 IL13 IL10 IGHE
19 keratitis, hereditary 31.0 TNF TLR4 NLRP3 IL6 IL10 CXCL8
20 chlamydia 31.0 TNF TLR4 IL6 IL5 IL4 IL10
21 allergic conjunctivitis 30.9 TNF TLR4 TLR3 RNASE3 IL5 IL4
22 atopic keratoconjunctivitis 30.9 RNASE3 IL5 IL4 IL2 IGHE IFNG
23 eye disease 30.8 TNF IL6 IL5 IL4 IL2 IL13
24 dacryoadenitis 30.8 IL4 IL13 IL10
25 pemphigoid 30.8 TNF IL5 IL4 IL13 IFNG CCL11
26 rubella 30.7 TNF TLR4 TLR3 IL6 IL5 IL4
27 urethritis 30.7 TNF TLR4 IL6 IL10 CXCL8
28 keratopathy 30.7 TNF IL4 ICAM1 CXCL8
29 scleritis 30.7 TNF IL5 IL4 IFNG
30 keratoconjunctivitis 30.7 TNF RNASE3 IL6 IL5 IL4 IL2
31 cytokine deficiency 30.7 IL5 IL13
32 iritis 30.6 TNF IL6 IL10
33 cellulitis 30.6 TNF RNASE3 IL6 IL5
34 endophthalmitis 30.6 TNF PLG IL6 ICAM1 CXCL8
35 iridocyclitis 30.5 TNF TLR4 IL6 IL10
36 pharyngitis 30.5 TNF NLRP3 IL6 CXCL8
37 tracheitis 30.4 TNF IL6 CXCL8
38 covid-19 30.4 TNF TLR4 NLRP3 IL6 IL4 CXCL8
39 ige responsiveness, atopic 30.4 RNASE3 IL5 IL4 IL13 IL10 IGHE
40 cholera 30.4 TNF IL6 IL4 IL10
41 rosacea 30.4 TNF IL6 IL33 CXCL8
42 pemphigus 30.3 TNF IL6 IL4 IL10
43 exanthem 30.3 TNF NLRP3 IL6 IL2 IL10 IFNG
44 poliomyelitis 30.3 TNF TLR3 IL4 IL10 IFNG ICAM1
45 hypopyon 30.3 TNF IL6 IL10
46 mycobacterium abscessus 30.3 TNF NLRP3 CXCL8
47 severe acute respiratory syndrome 30.3 TNF TLR4 IL6 IL10 IFNG CXCL8
48 vaginitis 30.2 TNF IL6 IL10 CXCL8
49 vulvovaginitis 30.2 IL10 CXCL8 CCL11
50 erythema multiforme 30.2 TNF IL6 IL5 IL4 IL2 IFNG

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis
Sources

Symptoms & Phenotypes for Conjunctivitis

About this section

UMLS symptoms related to Conjunctivitis:


bloodshot eye; conjunctival congestion; redness of eye; discharge from eye

MGI Mouse Phenotypes related to Conjunctivitis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 CCL11 HRH1 ICAM1 IFNG IL10 IL13
2 immune system MP:0005387 10.41 CCL11 HRH1 ICAM1 IFNG IL10 IL13
3 homeostasis/metabolism MP:0005376 10.4 HRH1 ICAM1 IFNG IL10 IL13 IL2
4 digestive/alimentary MP:0005381 10.39 ICAM1 IFNG IL10 IL13 IL2 IL33
5 cellular MP:0005384 10.37 ICAM1 IFNG IL10 IL13 IL2 IL33
6 growth/size/body region MP:0005378 10.37 HRH1 ICAM1 IFNG IL10 IL13 IL2
7 endocrine/exocrine gland MP:0005379 10.28 ICAM1 IFNG IL10 IL13 IL2 IL33
8 mortality/aging MP:0010768 10.25 HRH1 ICAM1 IFNG IL10 IL13 IL2
9 integument MP:0010771 10.2 ICAM1 IFNG IL10 IL13 IL33 IL4
10 liver/biliary system MP:0005370 10.17 HRH1 IFNG IL10 IL2 IL4 IL5
11 neoplasm MP:0002006 10.06 ICAM1 IFNG IL10 IL2 IL5 IL6
12 nervous system MP:0003631 10.03 ICAM1 IFNG IL10 IL13 IL33 IL4
13 muscle MP:0005369 9.97 ICAM1 IFNG IL10 IL13 IL6 TLR3
14 reproductive system MP:0005389 9.77 IFNG IL10 IL13 IL2 IL33 IL4
15 no phenotypic analysis MP:0003012 9.7 IFNG IL10 IL13 IL2 IL33 IL4
16 respiratory system MP:0005388 9.44 CCL11 IFNG IL10 IL13 IL2 IL33
Sources

Drugs & Therapeutics for Conjunctivitis

About this section

PubMed Health treatment related to Conjunctivitis: 62

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection , even though conjunctivitis is more commonly caused by viruses . But antibiotics are only effective against bacteria , and have no effect on viruses. If the infection is viral, only the symptoms can be treated. Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful. If conjunctivitis is caused by an allergy , it can be treated with allergy medicine such as antihistamines .

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 602)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Ferrous fumarate Approved Phase 4 141-01-5
3
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
4
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
7
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
8
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
9
Alcaftadine Approved Phase 4 147084-10-4 19371515
10
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
11
Dipivefrin Approved Phase 4 52365-63-6 3105
12
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
13
Montelukast Approved Phase 4 158966-92-8 5281040
14
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
15
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
16
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
17
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
18
Fosaprepitant Approved Phase 4 172673-20-0 219090
19
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
20
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
21
Insulin glargine Approved Phase 4 160337-95-1
22
Insulin lispro Approved Phase 4 133107-64-9
23
tannic acid Approved Phase 4 1401-55-4
24
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Norepinephrine Approved Phase 4 51-41-2 439260
27
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
30
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
31
Azathioprine Approved Phase 4 446-86-6 2265
32
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
33
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
34
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
35
Lopinavir Approved Phase 4 192725-17-0 92727
36
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
37
Zidovudine Approved Phase 4 30516-87-1 35370
38
Didanosine Approved Phase 4 69655-05-6 50599
39
Rilpivirine Approved Phase 4 500287-72-9 6451164
40
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
41
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
42
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
43
Iloperidone Approved Phase 4 133454-47-4 71360
44
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
45
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350
46
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
47
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
48
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
49
Lifitegrast Approved Phase 4 1025967-78-5
50
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8

Interventional clinical trials:

(show top 50) (show all 1021)
# Name Status NCT ID Phase Drugs
1 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
2 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
3 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaftâ„¢) Unknown status NCT01808768 Phase 4 Alcaftadine
4 Prospective, Randomized, Double-blinded, Placebo-controlled Study to Examine Pain Relief and the Need for Supplementary Analgesics With Intra-thecal Morphine Sulfate (0.2 mg) in Patients Undergoing Total Knee Arthroplasty (TKA) Unknown status NCT02620631 Phase 4 Morphine;Placebo
5 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
6 Safety and Efficacy of Intranasal Dexmedetomidine as a Sedative in Pediatric Dentistry: a Randomized, Double-blind Clinical Study Unknown status NCT02985697 Phase 4 Dexmedetomidine;Midazolam Hydrochloride;Nitrous Oxide
7 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
8 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
9 Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study Unknown status NCT01167062 Phase 4 Tamsulosin Hydrochloride OCAS 0.4 mg
10 Clinical Outcomes Following Non-Surgical Treatment of Chronic Periodontitis, Using Scaling and Root Planing (SRP) in Conjunction With PerioWave, Compared to SRP Alone Unknown status NCT00296881 Phase 4
11 Transforaminal Epidural Steroid Injection in Conjunction With Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for the Management of Chronic Lumbosacral Radicular Pain: a Randomized, Double-blind Trial Unknown status NCT02930057 Phase 4 Celestone;Control
12 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
13 Clinical Trial to Evaluate the Efficacy and Safety of SurgiFillâ„¢ on Spinal Fusion -Comparison Between Autograft Mixed With SurgiFillâ„¢ and Autograft in Spinal Fusion- Unknown status NCT02466048 Phase 4
14 A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy Unknown status NCT01657812 Phase 4 dexmedetomidine
15 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Completed NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
16 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Completed NCT01346371 Phase 4 Refresh Tears 0.5% Lubricant Eye Drops;Bepreve 1.5% Ophthalmic Solution
17 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
18 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
19 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
20 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
21 A Study to Evaluate the Efficacy of Lastacaft® Compared to Patadayâ„¢ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
22 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
23 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
24 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
25 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
26 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
27 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
28 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
29 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
30 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
31 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
32 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
33 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
34 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
35 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
36 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
37 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
38 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
39 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
40 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ® (Placebo)
41 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
42 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
43 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
44 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
45 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
46 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
47 Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazorac .1% Gel or Vehicle Gel Completed NCT00145106 Phase 4 Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
48 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
49 SAFER-SIM: Opiates and Benzodiazepines on Driving Completed NCT03447353 Phase 4 Xanax 1Mg Tablet;Norco 10Mg-325Mg Tablet;Placebo Oral Tablet
50 Comparative Evaluation of Dexamethasone and Dexmedetomidine as Adjuvants for Bupivacaine in Ultrasound Guided Infraorbital Nerve Block in Infants for Cleft Lip Repair Completed NCT03480607 Phase 4 Dexmedetomidine group;Dexamethasone group

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cromolyn
Cromolyn Sodium
Oxymetazoline
Oxymetazoline hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate

Cochrane evidence based reviews: conjunctivitis

Sources

Genetic Tests for Conjunctivitis

About this section

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 29
Sources

Anatomical Context for Conjunctivitis

About this section

MalaCards organs/tissues related to Conjunctivitis:

40
Eye, Skin, Bone, Liver, T Cells, Bone Marrow, Brain
Sources

Publications for Conjunctivitis

About this section

Articles related to Conjunctivitis:

(show top 50) (show all 11583)
# Title Authors PMID Year
1
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 61 54
20361659 2009
2
Traffic-related outdoor air pollution and respiratory symptoms in children: the impact of adjustment for exposure measurement error. 61 54
18379431 2008
3
IgE antibody on worn highly oxygen-permeable silicone hydrogel contact lenses from patients with contact lens-induced papillary conjunctivitis (CLPC). 54 61
18327049 2008
4
[Tumor necrosis factor receptor associated periodic syndrome (TRAPS). Report of two cases]. 54 61
17277873 2006
5
[Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis]. 54 61
16491868 2006
6
Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. 54 61
15245511 2004
7
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. 54 61
11443543 2001
8
Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. 61 54
11148813 2000
9
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 61 54
10756233 2000
10
Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. 54 61
9856836 1998
11
[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis]. 61 54
9759406 1998
12
Eosinophil granule proteins expressed in ocular cicatricial pemphigoid. 61 54
9602632 1998
13
Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. 54 61
8648032 1996
14
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. 61 54
8612470 1995
15
Ocular thelaziosis: A case report of an emerging zoonosis. 61
33718660 2021
16
Ocular Anterior Segment Pathology in the Emergency Department: A 5-Year Study. 61
32568931 2021
17
CLEAR - Contact lens complications. 61
33775382 2021
18
One-year Profile of Eye Diseases in Infants (PEDI) in secondary (rural) eye care centers in South India. 61
33727457 2021
19
Cost Savings From a Policy to Diagnose and Prevent Transmission of Adenoviral Conjunctivitis in Employees of a Large Academic Medical Center. 61
33792644 2021
20
Cell penetrating peptide TAT-functionalized liposomes for efficient ophthalmic delivery of flurbiprofen: Penetration and its underlying mechanism, retention, anti-inflammation and biocompatibility. 61
33647409 2021
21
Association between short-term exposure to ambient nitrogen dioxide and the risk of conjunctivitis in Hefei, China: A time-series analysis. 61
33515578 2021
22
Novel homozygous mutation of plasminogen in ligneous conjunctivitis: a case report and literature review. 61
33427557 2021
23
CLEAR - Effect of contact lens materials and designs on the anatomy and physiology of the eye. 61
33775377 2021
24
Conjunctivitis as initial presenting symptom in a COVID-19 patient. 61
33754132 2021
25
Real-world evidence costs of allergic rhinitis and allergy immunotherapy in the commercially insured United States population. 61
33754932 2021
26
Ocular manifestations in renal allograft recipients: An Indian perspective. 61
33727456 2021
27
Association between PM10 from vegetation fire events and hospital visits by children in upper northern Thailand. 61
33121762 2021
28
Clinical presentation of congenital syphilis in a rotavirus vaccine cohort study in Lusaka: a case series. 61
33789741 2021
29
Peanuts in the air - clinical and experimental studies. 61
33548082 2021
30
New Onset of Unilateral Orbital Myositis following Mild COVID-19 Infection. 61
33797304 2021
31
Draft genome sequence of a nontypeable Haemophilus influenzae strain used in the study of human respiratory infection. 61
33794985 2021
32
Mycoplasmas bovis P48 induces apoptosis in EBL cells via an endoplasmic reticulum stress-dependent signaling pathway. 61
33676093 2021
33
Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial. 61
33231925 2021
34
Risk factors prediction, clinical outcomes, and mortality in COVID-19 patients. 61
33247599 2021
35
AIDS Presenting in an Adolescent Male With Persistent Conjunctivitis and Eye Pain. 61
33280977 2021
36
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. 61
32946967 2021
37
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. 61
33332697 2021
38
Quinolone immediate hypersensitivity due to topical ophthalmic preparations: a case report and review of literature. 61
33112013 2021
39
Neonatal prophylaxis with antibiotic containing ointments does not reduce incidence of chlamydial conjunctivitis in newborns. 61
33731049 2021
40
Reducing suspicion of sexual abuse in paediatric chlamydial conjunctivitis using ompA genotyping. 61
33782064 2021
41
A "shining" example of interstitial keratitis. 61
33437893 2021
42
Bilateral methicillin-resistant Staphylococcus aureus keratitis after corneal crosslinking for keratoconus in a child. 61
33689909 2021
43
Clinical Spectrum and Outcomes of Ocular and Periocular Complications following External-Beam Radiotherapy for Inoperable Malignant Maxillary Sinus Tumors. 61
33796515 2021
44
Long-term remission of unusual plasmoacanthoma on the nasal canthus achieved by intralesional corticosteroid injection: Insights into the pathogenesis and treatment planning based on a literature review. 61
33739545 2021
45
The spectrum of allergic ocular diseases. 61
33276116 2021
46
Molecular Characterization of Coxsackievirus A24v from Feces and Conjunctiva Reveals Epidemiological Links. 61
33807540 2021
47
Detection of Coronavirus in Tear Samples of Hospitalized Patients With Confirmed SARS-CoV-2 From Oropharyngeal Swabs. 61
32897895 2021
48
A Patient With Bilateral Conjunctivitis Positive for SARS-CoV-2 RNA in a Conjunctival Sample. 61
32794685 2021
49
Pseudomembranous conjunctivitis with hand, foot and mouth disease in a pregnant woman : a case report. 61
33653308 2021
50
Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared. 61
32745569 2021
Sources

Variations for Conjunctivitis

About this section
Sources

Expression for Conjunctivitis

About this section
Search GEO for disease gene expression data for Conjunctivitis.
Sources

Pathways for Conjunctivitis

About this section

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.12 TNF TLR4 TLR3 RNASE3 NLRP3 IL6
2
ERK Signaling 63
Show member pathways
 13.89 TNF IL6 IL5 IL4 IL2 IL13
3
PEDF Induced Signaling 63
Show member pathways
 13.81 TNF TLR4 IL6 IL5 IL4 IL33
4
TGF-Beta Pathway 63
Show member pathways
 13.68 TNF IL6 IL5 IL4 IL2 IL13
5
Akt Signaling 63
Show member pathways
 13.56 TNF TLR4 TLR3 IL6 IL5 IL4
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.48 TNF IL6 IL5 IL4 IL33 IL2
7
PAK Pathway 63
Show member pathways
 13.43 TNF IL6 IL5 IL4 IL2 IL13
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.36 TNF TLR4 TLR3 NLRP3 IL6 IL2
9
PI3K-Akt signaling pathway 36
Show member pathways
 13.07 TNF TLR4 TLR3 IL6 IL4 IL2
10
Human cytomegalovirus infection 36
Show member pathways
 13.03 TNF TLR4 TLR3 IL6 ICAM1 CXCL8
11
Pathways in cancer 36
12.98 IL6 IL5 IL4 IL2 IL13 IFNG
12
Measles 36
Show member pathways
 12.93 TNF TLR4 TLR3 PLG NLRP3 IL6
13
IL-2 Pathway 63
Show member pathways
 12.9 TNF TLR4 TLR3 IL4 IL2 IFNG
14
Salmonella infection (KEGG) 36
Show member pathways
 12.81 TNF TLR4 NLRP3 IL6 CXCL8
15
T cell receptor signaling pathway 36
Show member pathways
 12.79 TNF TLR4 IL6 IL5 IL4 IL2
16
NF-KappaB Family Pathway 63
Show member pathways
 12.78 TNF TLR4 TLR3 IL6 IL2
17
Allograft rejection 36 1
Show member pathways
 12.78 TNF RNASE3 IL6 IL5 IL4 IL2
18
Immune response NFAT in immune response 23
Show member pathways
 12.77 TNF IL4 IL2 IL10 IGHE IFNG
19
Th17 cell differentiation 36
Show member pathways
 12.77 TNF TLR4 IL6 IL5 IL4 IL2
20
Immune response IL-23 signaling pathway 23
Show member pathways
 12.74 TNF PLG IL6 IL2 IL10 IFNG
21
NF-kappaB Signaling 4
12.71 TNF TLR3 IL4 IL2 IL10 IFNG
22
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.68 TNF IL5 IL4 IL13 IGHE
23
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.62 TNF IL4 IL2 IFNG ICAM1
24
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.62 TNF TLR4 TLR3 NLRP3 NLRP12 IL6
25
JAK-STAT signaling pathway 36
Show member pathways
 12.6 IL6 IL5 IL4 IL2 IL13 IL10
26
Selenium Micronutrient Network 1
Show member pathways
 12.53 TNF PLG IL6 IL4 IL2 IFNG
27
IL-17 Family Signaling Pathways 64
Show member pathways
 12.52 TNF IL6 IL5 IL4 IL13 IFNG
28
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.5 TNF IL6 IL2 IL10 CXCL8 CCL11
29
Toll Comparative Pathway 63
Show member pathways
 12.48 TNF TLR4 TLR3 IL6 IFNG CXCL8
30
Shigellosis 36
12.46 TNF TLR4 NLRP3 CXCL8
31
Development IGF-1 receptor signaling 23
Show member pathways
 12.45 IL4 IGHE HRH1 CCL11
32
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.43 TNF IL6 IL5 IL4 IL2 IL13
33
NOD-like receptor signaling pathway 36
12.42 TNF TLR4 NLRP3 NLRP12 IL6 CXCL8
34
Human T-cell leukemia virus 1 infection 36
12.41 TNF IL6 IL2 ICAM1
35
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.41 TNF TLR4 TLR3 IL6 CXCL8
36
Toxoplasmosis 36
Show member pathways
 12.4 TNF TLR4 IL4 IL10 IFNG
37
Necroptosis 36
Show member pathways
 12.39 TNF TLR4 TLR3 NLRP3 IL33 IFNG
38
Bacterial infections in CF airways 23
Show member pathways
 12.39 TNF TLR4 IL6 IL4 IFNG CXCL8
39
Tuberculosis 36
12.38 TNF TLR4 IL6 IL10 IFNG
40
C-type lectin receptor signaling pathway 36
Show member pathways
 12.36 TNF NLRP3 IL6 IL2 IL10
41
Colorectal Cancer Metastasis 63
12.34 TNF TLR4 TLR3 IL6 IFNG
42
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.33 TNF IL6 IL13 IL10 CXCL8
43
IL-1 Family Signaling Pathways 64
Show member pathways
 12.31 TNF IL6 IL33 CXCL8
44
Yersinia infection 36
12.29 TNF TLR4 NLRP3 IL6 IL2 IL10
45
MAPK Pathway 69
Show member pathways
 12.2 TLR4 TLR3 IL5 IL2 IL13
46
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.2 TNF IL6 IL5 IL4 IL2 IL10
47
Spinal Cord Injury 1
12.18 TNF TLR4 IL6 IL4 IL2 IFNG
48
Amoebiasis 36
12.14 TNF TLR4 IL6 IL10 IFNG CXCL8
49
Rheumatoid arthritis 36
12.08 TNF TLR4 IL6 IFNG ICAM1 CXCL8
50
NF-kappa B signaling pathway 36
12.06 TNF TLR4 ICAM1 CXCL8
Sources

GO Terms for Conjunctivitis

About this section

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF RNASE3 PLG NLRP3 IL6 IL5
2 external side of plasma membrane GO:0009897 9.55 TNF TLR4 IL13 IGHE ICAM1
3 extracellular space GO:0005615 9.5 TNF TLR3 RNASE3 PLG IL6 IL5

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 TLR4 TLR3 NLRP3 NLRP12 IL6 IL5
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TNF TLR4 TLR3 NLRP3 IL6 IL4
3 positive regulation of gene expression GO:0010628 10.16 TNF TLR4 TLR3 IL6 IL4 IL33
4 defense response to bacterium GO:0042742 10.09 TNF TLR4 TLR3 RNASE3 IL10 IGHE
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.05 TNF TLR4 ICAM1 CCL11
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.05 TNF TLR4 TLR3 NLRP3 IL6 ICAM1
7 defense response to virus GO:0051607 10.04 TLR3 IL6 IL33 IFNG
8 cellular response to lipopolysaccharide GO:0071222 10.04 TNF TLR4 NLRP3 IL6 IL10 ICAM1
9 negative regulation of inflammatory response GO:0050728 10.03 NLRP3 NLRP12 IL4 IL2 IL13 IL10
10 response to lipopolysaccharide GO:0032496 10.02 TLR4 IL13 IL10 ICAM1
11 defense response GO:0006952 10.01 TNF TLR3 NLRP3 CXCL8
12 response to ethanol GO:0045471 10 NLRP3 IL2 IL13 ICAM1
13 positive regulation of interleukin-6 production GO:0032755 10 TNF TLR4 TLR3 IL6 IL33 IFNG
14 response to virus GO:0009615 9.99 TNF TLR3 IFNG CCL11
15 positive regulation of DNA-binding transcription factor activity GO:0051091 9.99 TNF IL6 IL5 IL10
16 positive regulation of tumor necrosis factor production GO:0032760 9.98 TLR4 TLR3 IL6 IL33 IFNG
17 cellular response to interferon-gamma GO:0071346 9.97 TLR4 TLR3 ICAM1 CCL11
18 negative regulation of interleukin-6 production GO:0032715 9.97 TNF TLR4 NLRP12 IL10
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.96 TNF TLR4 TLR3 NLRP12
20 inflammatory response GO:0006954 9.96 TNF TLR4 TLR3 NLRP3 IL6 IL5
21 positive regulation of interferon-gamma production GO:0032729 9.95 TNF TLR4 TLR3 IL2
22 positive regulation of cytokine production GO:0001819 9.95 TNF TLR3 IL33 IL10 IFNG
23 positive regulation of inflammatory response GO:0050729 9.95 TNF TLR4 TLR3 NLRP12 IL33 IL2
24 cellular response to mechanical stimulus GO:0071260 9.94 TLR4 TLR3 IL13
25 positive regulation of interleukin-8 production GO:0032757 9.94 TNF TLR4 TLR3 IL6
26 negative regulation of tumor necrosis factor production GO:0032720 9.93 TLR4 IL4 IL10
27 regulation of insulin secretion GO:0050796 9.93 TNF IL6 IFNG
28 apoptotic signaling pathway GO:0097190 9.93 TNF TLR4 TLR3
29 positive regulation of B cell proliferation GO:0030890 9.93 TLR4 IL5 IL4 IL2 IL13
30 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 TNF IL6 IL4 IL2 IL13 IFNG
31 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
32 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.92 TNF TLR4 TLR3
33 extrinsic apoptotic signaling pathway GO:0097191 9.92 TNF TLR3 IL33 IFNG
34 positive regulation of nitric oxide biosynthetic process GO:0045429 9.92 TNF TLR4 IFNG ICAM1
35 positive regulation of T cell proliferation GO:0042102 9.91 IL6 IL4 IL2
36 positive regulation of smooth muscle cell proliferation GO:0048661 9.91 TNF IL6 IL13
37 humoral immune response GO:0006959 9.91 TNF IL6 IFNG
38 positive regulation of interleukin-10 production GO:0032733 9.91 TLR4 IL6 IL4 IL13
39 positive regulation of interleukin-1 beta production GO:0032731 9.91 TNF TLR4 NLRP3 NLRP12 IL6 IFNG
40 negative regulation of endothelial cell apoptotic process GO:2000352 9.9 IL4 IL13 IL10 ICAM1
41 negative regulation of interferon-gamma production GO:0032689 9.89 TLR4 IL33 IL10
42 positive regulation of JAK-STAT cascade GO:0046427 9.89 TNF IL6 IL5 IL10
43 positive regulation of interleukin-12 production GO:0032735 9.88 TLR4 TLR3 IFNG
44 microglial cell activation GO:0001774 9.88 TNF TLR3 IL4 IL13 IFNG
45 positive regulation of macrophage activation GO:0043032 9.87 TLR4 IL33 IL13 IL10
46 negative regulation of neurogenesis GO:0050768 9.85 TNF IL6 CCL11
47 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.85 TNF TLR4 IL6
48 negative regulation of osteoclast differentiation GO:0045671 9.85 TLR4 TLR3 IL4
49 positive regulation of chemokine production GO:0032722 9.85 TNF TLR4 TLR3 IL6 IL33 IFNG
50 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.84 TLR4 IL33 IFNG

Molecular functions related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF IL6 IL5 IL4 IL33 IL2
2 growth factor activity GO:0008083 9.35 IL6 IL5 IL4 IL2 IL10
Sources

Sources for Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51